Healthcare • Drug Manufacturers - Specialty & Generic
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ORGO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
18 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 9
135 filers reported a long position in ORGO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| MORGAN STANLEY | $28.5M | 11.7M | +0.9% |
| Soleus Capital Management, L.P. | $24.6M | 10.1M | +0.5% |
| BlackRock, Inc. | $17.6M | 7.2M | +48% |
| DIMENSIONAL FUND ADVISORS LP | $7.4M | 3.1M | +5.5% |
| AQR CAPITAL MANAGEMENT LLC | $7.3M | 3M | +241.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.1M | 2.9M | +0.2% |
| D. E. Shaw & Co., Inc. | $7M | 2.9M | +25.7% |
| Assenagon Asset Management S.A. | $4.8M | 2M | Unchanged |
| GEODE CAPITAL MANAGEMENT, LLC | $4.7M | 1.9M | +8.5% |
| DEUTSCHE BANK AG\ | $4.1M | 1.7M | 0% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.